The Common Cytokine Receptor gamma  Chain Plays an Essential Role in Regulating Lymphoid Homeostasis

By Hiroshi Nakajima,* Elizabeth W. Shores,Dagger Masayuki Noguchi,* and Warren J. Leonard*

From the * Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892; and the Dagger  Division of Hematologic Products, Food and Drug Administration, Bethesda, Maryland 20892

Summary
Materials and Methods
Results and Discussion
Footnotes
Acknowledgements
References


Summary

In the immune system, there is a careful regulation not only of lymphoid development and proliferation, but also of the fate of activated and proliferating cells. Although the manner in which these diverse events are coordinated is incompletely understood, cytokines are known to play major roles. Whereas IL-7 is essential for lymphoid development, IL-2 and IL-4 are vital for lymphocyte proliferation. The receptors for each of these cytokines contain the common cytokine receptor gamma  chain (gamma c), and it was previously shown that gamma c-deficient mice exhibit severely compromised development and responsiveness to IL-2, IL-4, and IL-7. Nevertheless, these mice exhibit an age-dependent accumulation of splenic CD4+ T cells, the majority of which have a phenotype typical of memory/activated cells. When gamma c-deficient mice were mated to DO11.10 T cell receptor (TCR) transgenic mice, only the T cells bearing endogenous TCRs had this phenotype, suggesting that its acquisition was TCR dependent. Not only do the CD4+ T cells from gamma c-deficient mice exhibit an activated phenotype and greatly enhanced incorporation of bromodeoxyuridine but, consistent with the lack of gamma c-dependent survival signals, they also exhibit an augmented rate of apoptosis. However, because the CD4+ T cells accumulate, it is clear that the rate of proliferation exceeds the rate of cell death. Thus, surprisingly, although gamma c-independent signals are sufficient to mediate expansion of CD4+ T cells in these mice, gamma c-dependent signals are required to regulate the fate of activated CD4+ T cells, underscoring the importance of gamma c-dependent signals in controlling lymphoid homeostasis.


The common cytokine receptor gamma  chain (gamma c)1 is the genetic defect in X-linked severe combined immunodeficiency (XSCID) (1) and is a shared component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (2). In humans with XSCID, the lack of functional gamma c results in profoundly diminished T cell development and an absence of natural killer (NK) cells. In contrast, B cell numbers are normal, although the B cells are nonfunctional with concomitant hypogammaglobulinemia. Mice in which the gamma c gene has been targeted by homologous recombination exhibit a related, but somewhat different phenotype (6). Like humans with XSCID, they have hypoplastic thymuses and lack NK cells. Unlike humans with XSCID, conventional B cells are greatly diminished in the bone marrow and the spleens of both young and adult gamma c-deficient mice, likely reflecting the key role of IL-7 as a pre-B cell growth factor in mice, but not in humans (5). In addition, these mice lacked visible gut-associated lymphoid tissue and peripheral lymph nodes were essentially absent. Although splenic T cells are diminished in number at 3 wk of age, CD4+ T cells, but not CD8+ T cells, dramatically accumulate in the spleen in an age-dependent manner. Moreover, the finding of CD4+ T cell infiltrates, particularly in the gut in association with colitis, suggested that the CD4+ T cells might be activated and involved in mediating the pathological changes found in these mice. Given that the mice are compromised in their ability to respond to gamma c-dependent cytokines including IL-2, IL-4, and IL-7 (6), this accumulation of CD4+ T cells was unexpected. We now have performed studies to characterize further these CD4+ T cells to understand better the role of gamma c in development of the immune response in vivo.


Materials and Methods

Mice and Genetic Analysis. The gamma c-deficient mice (7) used in these studies were back-crossed to either C57BL/6 (B6) (H-2b/b) or BALB/c mice (H-2d/d) (Jackson Laboratory, Bar Harbor, ME) for three/four generations. Since the gamma c gene is localized on X chromosome, DO10 TCR transgenic male mice (H-2d/d), specific for ovalbumin (9), were mated with BALB/c gamma c+/- heterozygous female mice. These matings yielded four genotypes of male mice (DO10-gamma c+/Y, DO10+gamma c+/Y, DO10-gamma c-/Y, and DO10+gamma c-/Y). Similarly, AND TCR transgenic male mice (H-2b/b), specific for cytochrome c (10, 11), were mated with B6 gamma c+/- female mice. Mice were housed in microisolator cages under pathogen-free conditions. The mice were genotyped by PCR of tail DNA using the following primer pairs: to detect the wild-type gamma c gene, 5'-CTTTATTGATAACGATCTATCCCTCACCC-3' and 5'CTCCACTCTGCAGAGTCTATGGAATCC-3'; to detect the gamma c knockout gene, 5'-GCTGACAGCCGGAACACGGCGG-3' and 5'-GTGCAATCCATCTTGTTCAATGGCCG-3'; to detect the DO10 transgene, 5'-CAGGAGGGATCCAGTGCCAGC-3' and 5'-TGGCTCTACAGTGAGTTTGGT-3'; to detect the AND transgene, 5'-GACTTGGAGATTGCCAACCCATATCTAAGT-3' and 5'-TGAGCCGAAGGTGTAGTCGGAGTTTGCATT-3'.

Flow Cytometric Analysis. Cells from thymus and spleen were stained and analyzed on a FACSort® (Becton Dickinson, San Jose, CA) using Lysis II software (7). For direct staining, the following conjugated antibodies were purchased from PharMingen (San Diego, CA): anti-CD4 Cy-Chrome (H129.19), anti-CD8 PE (53-6.7), anti-CD25 PE (7D4), anti-CD44 Cy-Chrome (IM7), anti-CD45R (B220) PE (RA3-6B2), anti-CD49d FITC (R1-2), anti-CD62L PE (MEL-14), anti-CD69 PE (H1.2F3), anti-CTLA-4 PE (UC104F10-11), anti-erythroid cells PE (TER-119), anti-Fas biotin (Jo2), anti-I-Ab FITC (AF6-120.1), anti-I-Ad PE (AMS-32.1), anti-TCR Valpha 11 FITC (RR8-1), and anti-Qa2a biotin (1-9-9) (12). KJ1-26 mAb, anti-idiotype for DO10 TCR (13) (provided by Dr. B.J. Fowlkes), was purified from supernatants of hybridoma cells using protein G columns (Pharmacia, Uppsala, Sweden) and conjugated to FITC.

Splenic CD4+ T Cell Purification. Since erythroblastoid cells and macrophages were increased in the spleens of gamma c-deficient mice as compared with wild type mice, single cell suspensions from spleen were treated with ACK lysing buffer to remove red cells, stained with PE-conjugated anti-CD8 mAb (53-6.7, PharMingen) and PE-conjugated anti-erythroid mAb (TER-119, PharMingen) and anti-CD16/CD32 mAb (Fcgamma RIII/II receptor, 2.4G2, PharMingen), washed twice with 1 × PBS containing 1% BSA (PBS, 1% BSA), and applied to T cell enrichment columns (R&D Systems). The resulting cells from both wild-type and gamma c-deficient mice were 88-95% pure CD4+ T cells (average 91.8%) as determined by flow cytometry.

Cell Survival Assay. Purified CD4+ T cells were cultured in RPMI-1640 media supplemented with 10% charcoal-treated fetal bovine serum (Cocalico Biological, Inc., Reamstown, PA), 2 mM glutamine, and antibiotics for 8 to 48 h. Cells were harvested and stained with 5 µg/ml of propidium iodide (PI) (Boehringer Mannheim) and analyzed by flow cytometry.

Annexin V Staining. After cells were stained with anti-CD4 Cy-Chrome and washed twice with PBS, 1% BSA, cells were stained with annexin V FITC (R&D Systems) according to the instructions of the manufacturer. Cells were analyzed on a FACSort®.

TUNEL Method. The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) method was performed according to the instructions of the manufacturer (Boehringer Mannheim). Splenocytes were stained with anti-CD4 CyChrome and washed with PBS, 1% BSA. Cells were then fixed with 70% ethanol for 20 min at 4°C, treated with PBS containing 1% paraformaldehyde and 0.01% Tween-20 for 30 min at 25°C, washed once with PBS, and incubated with the fluoresceinlabeled TUNEL reaction mix for 60 min at 37°C. As a negative control, cells were incubated without TdT. Cells were then washed with PBS, 1% BSA and analyzed on a FACSort®.

Intracellular Staining of Bcl-2. Bcl-2 levels in CD4+ T cells were analyzed as previously described (14). In brief, splenocytes (1 × 106) were permeabilized in PBS, 1% BSA containing 0.04% saponin (saponin buffer) and incubated with anti-Bcl-2 mAb (clone 3F11, PharMingen, 2 µg/ml final concentration) or purified hamster IgG as a negative control (4°C for 30 min). Cells were washed twice with saponin buffer, incubated with anti-hamster IgG cocktail conjugated to FITC (clone G70-204, G94-56, G91140, PharMingen) (4°C for 30 min), washed once with saponin buffer and once with PBS, 1% BSA, then stained with antiCD62L PE/and anti-CD4 Cy-Chrome, and analyzed on a FACSort®.

In Vivo Bromodeoxyuridine (BrdU) Uptake and BrdU Staining. 8 to 12-wk-old gamma c-deficient or littermate control mice were injected i.p. with 750 µg of BrdU (Sigma) in 250 µl of PBS at time 0 and again at 4 h. Control mice were injected with PBS. 16 h after the second injection, thymocytes and purified splenic CD4+ T cells were fixed with 70% ethanol for 30 min on ice, denatured with 2 N HCl containing 0.5% Triton X-100 for 30 min to produce single-stranded DNA, and neutralized with 0.1 M sodium tetraborate, pH 9.0 (Sigma). Cells were resuspended in PBS, 1% BSA containing 0.5% Tween-20, stained with anti-BrdU FITC (Becton Dickinson) for 30 min at 25°C, washed once with PBS, 1% BSA containing 0.5% Tween-20, resuspended in PBS, 1% BSA, and analyzed on a FACSort®.

Apparent Rates of Replication and Survival. Assuming that cells that have taken up BrdU at 20 h have divided once, the apparent replication rate/day, r, can be calculated from the equation: percent BrdU uptake/20 h × 24 h/d = 2r/(100 r). Based on the data in Fig. 1 D, this yields values for r of 21.43%/d for gamma c-deficient mice and 6.32%/d for wild-type mice. Assuming that no death occurs and that there is no new migration of cells from thymus to periphery (neither assumption is likely to be correct), we can estimate the number of cells that might exist after 63 d of growth (from 3-12 wk of age) as 1.3 × 106 × (1.2143)63 = 2.66 × 1011 CD4+ splenic T cells instead of 5.28 × 107 cells for gamma c-deficient mice and 9.1 × 106 × (1.0632)63 = 4.31 × 108 cells instead of 1.67 × 107 for wild-type mice. Although not accurate, these calculations suggest that survival rates for the cells differ between the wild-type and gamma c-deficient mice. Again, assuming no new migration from the thymus to periphery and a constant replication rate, the survival rate/day can be estimated as ~87% for gamma c-deficient mice and 95% for wild-type mice, suggesting that cells from the gamma c-deficient mice had an increased rate of cell death (see below).


Fig. 1. Activated CD4+ T cells accumulate in an age-dependent fashion in gamma c-deficient mice and exhibit increased BrdU uptake. (A) The number of splenic CD4+ T cells in gamma c-deficient (closed diamonds) and wildtype (open squares) mice was calculated as the product of the number of splenocytes and the percent of CD4+ T cells, based on staining with antiCD4 Cy-Chrome and analysis on a FACSort® (Becton Dickinson) using Lysis II software. Shown are mean ± SEM (n = 4-9 at each timepoint). (B) Size of CD4+ T cells. Splenocytes from 6-wk-old mice were stained with anti-CD4 Cy-Chrome and PI, and cell size of viable cells was assessed by forward light scatter (FSC); data are shown on a linear scale. (C) Activation markers expressed on CD4+ T cells. Splenocytes were stained with anti-CD4 Cy-Chrome and either PE conjugated anti-CD62L (L-selectin), anti-CD69, or anti-CD25. Data were gated on CD4+ cells and displayed on a log scale. The data shown are representative of six experiments. (D) BrdU uptake of thymocytes and splenic CD4+ T cells. Mice were injected twice with BrdU (see Material and Methods). 16 h after the second injection, purified splenic CD4+ T cells and thymocytes were stained with anti-BrdU FITC according to the Becton Dickinson protocol and analyzed on a FACSort®. Histograms show BrdU staining (log scale); the numbers above the gate represent the mean percentage of BrdU-positive cells from four experiments. When mice were injected with PBS instead of BrdU, less than 0.1% of thymocytes and splenic CD4+ T cells were stained with anti-BrdU FITC (data not shown).
[View Larger Version of this Image (23K GIF file)]


Results and Discussion

Like humans with XSCID, gamma c-deficient mice have hypoplastic thymi and lack NK cells (5). However, peripheral T cells are generally not found in humans with XSCID (4), whereas peripheral CD4+ T cells are found in the gamma cdeficient mice (5). Although these cells are diminished in numbers in gamma c-deficient mice at 3 wk of age (6, 7), in most mice there is a dramatic age-dependent accumulation of these cells (7) (Fig. 1 A), even though the thymus remains small (7). Analysis using a series of different TCR Vbeta -specific mAbs (Vbeta 2, Vbeta 3, Vbeta 4, Vbeta 5.1,5.2, Vbeta 6, Vbeta 8.1,8.2, Vbeta 10, and Vbeta 11) indicated that the CD4+ T cell accumulation was polyclonal (unpublished data). Interestingly, the splenic CD4+ T cells in gamma c-deficient mice were increased in size (Fig. 1 B). The large size of the cells, coupled with the finding of CD4+ T cell infiltrates, particularly in the gut in association with colitis (5, 7), suggested that the CD4+ T cells might be activated and involved in mediating the pathological changes found in these mice. Therefore, we investigated the basis for the CD4+ T cell expansion.

A striking difference between splenic CD4+ T cells from gamma c-deficient and wild type mice was that the cells from the gamma c-deficient mice exhibited a CD62LlowCD69high phenotype typical of memory/activated cells, whereas those from wild-type mice exhibited a CD62LhighCD69low phenotype typical of naive cells (Fig. 1 C) (15). Interestingly, CD4+ T cells in mice deficient in IL-2 (16, 17), IL-2Ralpha (18), and IL-2Rbeta (19) also exhibited activated phenotypes. Expression of CD49d (VLA-4 alpha  chain) and CD44 was slightly increased in gamma c-deficient CD4+ T cells (data not shown), whereas no significant difference was seen in expression of IL-2Ralpha (CD25) (Fig. 1 C), or in CD40L, CD28, CTLA-4, or in Fas (data not shown). The lack of increase in these activation markers suggested that these cells were partially rather than fully activated and that gamma c-dependent signals are required for completing T cell activation. In contrast with the different phenotypes in splenic T cells, CD4+CD8- thymocytes from gamma c-deficient mice and wild type mice expressed similar levels of CD62L, CD69, and Qa-2a (data not shown).

The accumulation and activation of the CD4+ T cells appeared to result from a defect in T cells, because the defect was corrected in mice in which gamma c expression was selectively reconstituted in T cells (transgenic mice in which gamma c is under control of the CD3delta enhancer and promoter) but not in mice in which gamma c expression was selectively reconstituted in B cells (transgenic mice in which gamma c is under control of the mb-1 promoter and Eµ heavy chain enhancer) (data not shown). A similar activated phenotype in Jak3-deficient mice was corrected when these mice were reconstituted with Jak3 under control of the Lck promoter (19a), a finding consistent with the similar phenotypes in mice and humans deficient in either gamma c or Jak3 and with the conclusion that Jak3 is the major mediator of gamma c-dependent signals (4, 5).

Next, we investigated whether the CD62LlowCD69high phenotype of the gamma c-deficient splenic CD4+ T cells reflected active proliferation and found that bromodeoxyuridine (BrdU) uptake in these cells was greater than in wild-type mice (Fig. 1 D, left). In contrast, gamma c-deficient thymocytes exhibited lower BrdU uptake than wild-type thymocytes (Fig. 1 D, right). Thus, there was more active cell division in the spleens than in the thymi of adult gamma c-deficient mice, correlating with the activated phenotype of the gamma c-deficient splenocytes. It is important to recognize that because these mice were not subjected to thymectomy, some splenic BrdU uptake could have occurred in thymocytes before CD4+ T cell migration to the periphery; however, because the thymi in gamma c-deficient mice are very small (0.5-5% of littermate controls) and the BrdU uptake in thymocytes in these mice was lower than in wild-type mice, it is likely that the majority of BrdU uptake occurred in the periphery.

Based on the BrdU uptake studies, the gamma c-deficient mice had an apparent replication rate much greater than wildtype mice (21.43%/d for gamma c-deficient mice and 6.32%/d for wild-type mice; see Materials and Methods). Such an increased rate for the gamma c-deficient mice should have yielded a much greater accumulation of cells than actually seen (Fig. 1 A), suggesting that CD4+ T cells from the gamma c-deficient mice had an increased rate of cell death (see Materials and Methods). Indeed, when cultured without stimulation, purified splenic CD4+ T cells from gamma c-deficient mice exhibited a higher level of death than cells from wild-type mice, with the greatest difference occurring in the first 8 h (Fig. 2 A). Increased apoptosis was confirmed both by TUNEL analysis (data not shown) and by staining with annexin V (Fig. 2 B), which allows the detection of apoptotic cells at an early stage because of its selective affinity for phospholipids, especially phosphatidylserine (PS), which is exposed on the cell surface in apoptotic cells, while normally PS is restricted to the inner cell membrane (20). The rapid increase in death seen at 8 h in gamma c-deficient mice (Fig. 2 A) presumably is accounted for by the large number of cells that stained with annexin V at time 0 (Fig. 2 B), suggesting that splenic CD4+ T cells of gamma c-deficient mice may be primed to die by apoptosis in vivo. Bcl-2 levels correlate with the survival of lymphoid cells (23, 24) and are induced by gamma c-dependent cytokines that protect against apoptosis (25). Therefore, it was interesting that gamma c-deficient splenic CD4+ T cells expressed very low levels of Bcl-2 (Fig. 2 C) (including both CD62Lhigh and CD62Llow subpopulations; data not shown), suggesting that gamma c is required for maintaining the normal levels of Bcl-2 expression in both activated and naive peripheral CD4+ T cells.


Fig. 2. Augmented cell death and diminished Bcl-2 expression in gamma c-deficient CD4+ T cells. (A) Spontaneous cell death in vitro. Purified splenic CD4+ T cells from 6-wk-old mice were cultured in RPMI medium containing 10% charcoal-treated fetal bovine serum (Cocalico Biological, Inc.) for 8-48 h, harvested, and cell survival determined by staining with 5 µg/ml of PI, followed by analysis using a FACSort®. Data for each mouse were analyzed in duplicate. Shown are the means ± SD of three mice in each group. At time 0, approximately 98% of cells from wild-type and 93% of cells from gamma c-deficient mice were PI negative. (B) Annexin V binding to CD4+ T cells. Splenocytes from 6-wk-old mice were stained with anti-CD4 Cy-Chrome and then with annexin V FITC. Annexin V binding (log scale) is shown for CD4+ PI- cells. (C) Bcl-2 expression in splenic CD4+ T cells was analyzed approximately as previously described (14). The histograms show profiles for staining with anti-Bcl-2 (closed histograms) and control IgG (open histograms) in wild-type and gamma c-deficient mice (log scale).
[View Larger Version of this Image (22K GIF file)]

There are at least two possible explanations for why peripheral CD4+ T cells in gamma c-deficient mice were already activated without exogenous stimulation. In the first model, the activated phenotype does not require TCR stimulation (TCR-independent activation model); instead, gamma c-dependent signals are required for keeping mature CD4+ T cells in a naive stage and, that without such signals, these cells are activated nonspecifically. In the second model, peripheral CD4+ T cells in gamma c-deficient mice respond to self- or environmental antigens (TCR-dependent activation model). We investigated these possibilities using mice expressing MHC class II-restricted transgenic TCRs specific for ovalbumin (DO10 mice) or cytochrome c (AND mice). In these experiments, the mice were not exposed to the specific antigens. In DO10 male mice deficient in gamma c (DO10+gamma c-/Y mice), far fewer splenocytes were found than in DO10-gamma c-/Y mice (6.4 × 106 versus 79 × 106 cells/spleen) (Fig. 3 A). Analogous differences were also seen between AND+gamma c-/Y and AND-gamma c-/Y mice (2.7 × 106 versus 50 × 106 cells/ spleen). These data suggested that endogenous TCR expression might be important in regulating CD4+ T cell accumulation. Using the DO10+gamma c-/Y mice, we compared the relative frequency of memory (CD62Llow) and naive (CD62Lhigh) phenotypes in splenic CD4+ T cells expressing transgenic (KJ1-26+) versus endogenous (KJ1-26-) TCRs. Approximately 70% of CD4+ T cells from DO10+gamma c-/Y mice express the transgenic TCR (Fig. 3 B, fourth histogram), analogous to DO10+gamma c+/Y mice (second histogram). Surprisingly, although relatively high numbers of KJ126+CD4+ T cells in DO10+gamma c-/Y mice were CD62Lhigh (naive phenotype), similar to the finding for DO10+gamma c+/Y mice (84.9% versus 84.6%) (Fig. 3 C, bottom), relatively few of the endogenous KJ1-26- CD4+ T cells in DO10+gamma c-/Y mice were CD62Lhigh (10%), similar to the finding for DO10-gamma c-/Y mice (8.3%) (Fig. 3 C, top). Thus, the CD62Llow phenotype correlated with the presence of endogenous TCRs. Analogous results were found in AND TCR transgenic gamma c-deficient (AND+gamma c-/Y) mice. In AND+gamma c-/Y mice, 93% of transgenic TCR+ (Valpha 11+) CD4+ T cells were CD62Lhigh, similar to AND+gamma c+/Y mice (94%). These results support the TCR-dependent activation model and suggested that TCR(s) expressed on expanding peripheral CD4+ T cells in gamma c-deficient mice are specific for self-antigen or environmental antigens. The finding that over 80% of adult gamma c-deficient mice (C57BL/6 background) develop an inflammatory bowel disease (data not shown) is consistent with the possibility of self-reactive CD4+ T cells in these mice.


Fig. 3. Activation of splenic CD4+ T cells in gamma c-deficient mice is TCR dependent. gamma c-deficient mice were back-crossed to BALB/c mice (H-2d/d, Jackson Laboratory) for three generations. Since the gamma c gene is located on the X chromosome, DO10 TCR transgenic male mice (H-2d/d) were mated with BALB/c gamma c+/- heterozygous female mice (H-2d/d). These matings yielded four genotypes (assessed by PCR of tail DNA) of male mice (DO10-gamma c+/Y, DO10+gamma c+/Y, DO10-gamma c-/Y, and DO10+gamma c-/Y) (A). In (A), also shown are the total number and CD4/CD8 staining of splenocytes from 5-wk-old mice. As previously reported (32), DO10+ male mice expressing wild-type gamma c (DO10+gamma c+/Y mice) exhibit an increased CD4/CD8 ratio as compared with DO10-gamma c+/Y mice (first two panels), but consistent with the increased CD4/CD8 ratios previously observed in gamma c-deficient mice (6, 7), DO10+gamma c-/Y mice exhibited an even greater CD4/CD8 ratio (fourth panel). Results are representative of three separate experiments. (B) Histograms of KJ1-26 mAb (anti-idiotype TCR) staining (gated on CD4+ T cells). (C) Splenocytes were stained by three color flow cytometric analysis for expression of KJ1-26, CD62L, and CD4. Data were gated on KJ1-26- CD4+ (endogenous TCR) (top histogram) or KJ1-26+CD4+ (transgenic TCR) (bottom histogram) T cells. The histograms show profiles for CD62L expression (log scale); the percent of CD62Lhigh cells is indicated.
[View Larger Version of this Image (38K GIF file)]

In the immune response, there is a careful balance between clonal expansion and clonal deletion (29). Clonal expansion is believed to be regulated by mitogenic cytokines, especially IL-2. In gamma c-deficient mice, it was therefore surprising that although splenic T cells exhibit diminished in vitro responsiveness to mitogens (5), there was TCRdependent activation and a marked expansion of CD4+ T cells in vivo. In addition to this in vivo proliferation, we also detected an augmented rate of apoptosis in gamma c-deficient CD4+ T cells, a finding consistent with the known action of gamma c-dependent cytokines as survival factors (25); nevertheless, it was evident that the overall rate of death was inadequate for the degree of proliferation. Although the CD4+ T cells were activated, they expressed only low levels of CD25, CTLA-4, and Fas. Therefore, it is conceivable that gamma c-dependent signals are required to achieve induction of pathways that are required to negatively regulate immune responses. Thus, gamma c-dependent signals are essential components of a carefully controlled homeostatic mechanism that regulates the fate of activated cells.


Footnotes

Address correspondence to Warren J. Leonard, Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, Building 10, Room 7N244, 9000 Rockville Pike, Bethesda, MD 20892.

Received for publication 6 August 1996

   H. Nakajima was supported in part by Japan Society for the Promotion of Science and The Naito Foundation.
   1Abbreviations used in this paper: gamma c, common cytokine receptor gamma  chain; PI, propidium iodide; TUNEL, terminal deoxynucleotide transferase (TdT)- dUTP nick end-labeling; XSCID, X-linked severe combined immunodeficiency.

We thank D.Y. Loh for DO10 mice and the sequences of primers for detecting the DO10 transgene, S.M. Hedrick for AND mice, L. Berg for the sequences of primers for detecting the AND transgene, T. Tran for assistance with purification and labeling of KJ1-26 mAb, M. Murakami for valuable discussions, and R. Germain for critical comments.


References

1. Noguchi, M., H. Yi, H.M. Rosenblatt, A.H. Filipovich, S. Adelstein, W.S. Modi, O.W. McBride, and W.J. Leonard. 1993. Interleukin-2 receptor gamma  chain mutation results in X-linked severe combined immunodeficiency in human. Cell. 73: 147-157 [Medline] .
2. Leonard, W.J., M. Noguchi, R.M. Russell, and O.W. McBride. 1994. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma  chain as a common gamma  chain, gamma c. Immunol. Rev. 138: 61-86 [Medline] .
3. Sugamura, K., H. Asao, M. Kondo, N. Tanaka, N. Ishii, M. Nakamura, and T. Takesha. 1995. The common gamma -chain for multiple cytokine receptors. Adv. Immunol. 59: 225-277 [Medline] .
4. Leonard, W.J.. 1996. The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 47: 229-239 [Medline] .
5. Leonard, W.J., E.W. Shores, and P.E. Love. 1995. Role of the common cytokine receptor gamma  chain in cytokine signaling and lymphoid development. Immunol. Rev. 148: 97-114 [Medline] .
6. DiSanto, J.P, W. Müller, D. Guy-Grand, A. Fischer, and K. Rajewsky. 1995. Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor gamma  chain. Proc. Natl. Acad. Sci. USA. 92: 377-381 [Abstract] .
7. Cao, X., E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsall, S.M. Russell, J. Drago, M. Noguchi, A. Grinberg, E.T. Bloom, et al . 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma  chain. Immunity. 2: 223-238 [Medline] .
8. Ohno, K., T. Suda, M. Hashiyama, A. Mantani, M. Ikebe, K. Miyakawa, M. Moriyama, M. Nakamura, M. Katsuki, K. Takahashi, et al . 1996. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma  chain. Blood. 87: 956-969 [Abstract/Free Full Text] .
9. Murphy, K.M., A.B. Heimberger, and D.Y. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+ CD8+ TCRlo thymocytes in vivo. Science (Wash. DC). 250: 1720-1723 [Medline] .
10. Kaye, J., M.-L. Hsu, M.-E. Sauron, S.C. Jameson, N.R.J. Gascoigne, and S.M. Hedrik. 1989. Selective development of CD4+ T cells in transgenic mice expressing a class II MHCrestricted antigen receptor. Nature (Lond.). 341: 746-749 [Medline] .
11. Vasquez, N.J., J. Kaye, and S.M. Hedrick. 1992. In vivo and in vitro clonal deletion of double-positive thymocytes. J. Exp. Med. 175: 1307-1316 [Abstract] .
12. Ramsdell, F., M. Jenkins, Q. Dinh, and B.J. Fowlkes. 1991. The majority of CD4+CD8- thymocyte are functionally immature. J. Immunol. 147: 1779-1785 [Abstract/Free Full Text] .
13. Marrack, P., R. Shimonkevitz, C. Hannum, K. Haskins, and J. Kappler. 1983. The major histocompatibility complex- restricted antigen receptor on T cells. IV. An antiidiotypic antibody predicts both antigen and I-specificity. J. Exp. Med. 158: 1635-1646 [Abstract] .
14. Veis, D.J., C.L. Sentman, E.A. Bach, and S.J. Korsmeyer. 1993. Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J. Immunol. 151: 2546-2554 [Abstract/Free Full Text] .
15. Swain, S.L., L.M. Bradley, M. Croft, S. Tonkonogy, G. Atkins, A.D. Weinberg, D.D. Duncan, S.M. Hedrick, R.W. Dutton, and G. Huston. 1991. Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol. Rev. 123: 115-144 [Medline] .
16. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A.G. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75: 253-261 [Medline] .
17. Sadlack, B., J. Löhler, H. Schorle, G. Klebb, H. Haber, E. Sickel, R.J. Noelle, and I. Horak. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25: 3053-3059 [Medline] .
18. Willerford, D.M., J. Chen, J.A. Ferry, L. Davidson, A. Ma, and F.W. Alt. 1995. Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 3: 521-530 [Medline] .
19. Suzuki, H., T.M. Kündig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. Schmits, J.J.L. Simard, P.S. Ohashi, H. Griesser, et al . 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta . Science (Wash. DC). 268: 1472-1476 [Medline] .
19a. Thomis, D.C., and L.J. Berg. 1997. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med 185: 197-206 [Abstract/Free Full Text] .
20. Fadok, V.A., D.R. Voelker, P.A. Campbell, J.J. Cohen, D.L. Bratton, and P.M. Henson. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148: 2207-2216 [Abstract/Free Full Text] .
21. Andree, H.A.M., C.P.M. Reutelingsperger, R. Hauptmann, H.C. Hemker, W.T. Hermens, and G.M. Willems. 1990. Binding of vascular anticoagulant alpha  (VACalpha ) to planar phospholipid bilayers. J. Biol. Chem. 265: 4923-4928 [Abstract/Free Full Text] .
22. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V.  J. Immunol. Method. 184: 39-51 [Medline] .
23. Linette, G.P., and S.J. Korsmeyer. 1994. Differentiation and cell death: lessons from the immune system. Curr. Opin. Cell Biol. 6: 809-815 [Medline] .
24. Yang, E., and S.J. Korsmeyer. 1996. Molecular thanatopsis: a discourse on the Bcl2 family and cell death. Blood. 88: 386-401 [Free Full Text] .
25. Otani, H., M. Erdos, and W.J. Leonard. 1993. Tyrosine kinase(s) regulate apoptosis and bcl-2 expression in a growth factor-dependent cell line. J. Biol. Chem. 268: 22733-22736 [Abstract/Free Full Text] .
26. Deng, G., and E.R. Podack. 1993. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc. Natl. Acad. Sci. USA. 90: 2189-2193 [Abstract] .
27. Boise, L.H., A.J. Minn, C.H. June, T. Lindsten, and C.B. Thompson. 1995. Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl. Acad. Sci. USA. 92: 5491-5495 [Abstract] .
28. Akbar, A.N., N.J. Borthwick, R.G. Wickremasinghe, P. Panayiotidis, D. Pilling, M. Bofill, S. Krajewski, J.C. Reed, and M. Salmon. 1996. Interleukin-2 receptor common gamma -chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bclxS) gene expression. Eur. J. Immunol. 26: 294-299 [Medline] .
29. Green, D.R., and D.W. Scott. 1994. Activation-induced apoptosis in lymphocytes. Curr. Opin. Immunol. 6: 476-487 [Medline] .
30. Abbas, A.K.. 1996. Die and let live: eliminating dangerous lymphocytes. Cell. 84: 655-657 [Medline] .
31. Lenardo, M.J.. 1996. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183: 721-724 [Medline] .
32. Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1: 327-339 [Medline] .